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Abstract 
The mechanism of morphologic hange of human cultured umbilical vein endothelial cells (HUVECs) caused by fibrin was 
investigated. Ancrod, a thrombin-like enzyme, did not cause morphologic alteration of HUVEC by itself at concentrations ranging from 
0.01 to 10 U/ml. However, when 0.02 U/ml of ancrod was added to cultured HUVEC monolayers in the presence of citrated plasma, it
caused pronounced morphologic change of HUVEC after 6-10 h incubation period. Gly-Pro-Arg-Pro (4 mg/ml), an inhibitor of fibrin 
polymerization, prevented the morphologic alteration, indicating that the morphologic alteration was caused by the polymerized fibrin. 
The morphologic change of HUVEC caused by ancrod-generated fibrin was not observed in the presence of an intracellular calcium 
mobilization i hibitor TMB-8 (50/xM), and the morphologic alteration was also less pronounced with BAPTA(I5 /xM)-loaded HUVECs 
and HUVECs pretreated with EGTA (1.2 mM). Ancrod (in Medium 199) itself did not stimulate phosphoinositide br akdown of HUVEC. 
However, when ancrod was present in plasma, it caused an increase of [3H]IP1 of HUVECs preloaded with [3H]myoinositol. This IP 1 
increment was inhibited by Gly-Pro-Arg-Pro. The increase of IP 1 was significantly inhibited by the pretreatment of monoclonal ntibodies 
23C6 and 7E3 directed against a V/33 integrin. Neomycin (1 mM) and pertussis toxin (100 ng/ml), but not aspirin or mepacrine, blocked 
this enhanced phosphoinositide breakdown. The morphologic change was also prevented by the monoclonal ntibodies, 23C6 and 7E3. 
These results uggest that both intra- and extra-cellular calcium participate in the event of morphoiogic change of HUVEC caused by 
ancrod-generated fibrin, and the morphologic change is mediated, at least in part, by fibrin binding to integrin a v/33 on HUVECs, 
causing the subsequent activation of the endogenous G-protein coupled phospholipase C. 
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1. Introduction 
Endothelial cells play an important role in the regula- 
tion of vascular tone [ 1,2], cellular growth, differentiation, 
immune and inflammatory responses [3-5]. The vascular 
endothelium also contributes anticoagulant as well as pro- 
coagulant activities in regulating coagulation system. It 
produces a number of substances such as the Von Wille- 
brand factor [6], tissue factor [7] and tissue-type plasmino- 
gen activation or inhibitor of plasminogen activation [8,9]. 
When blood vessels get injured, the formation of fibrin 
stabilizes the hemostatic plug and supports wound healing 
and revascularization. Pathologically, various states of dis- 
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ease may destroy the balance between pro-and anti- 
coagulant state and subsequently ead to a generalized or 
local deposition of fibrin on the endothelial cell surface at 
the sites of thrombosis and inflammation [10]. 
The effect of fibrin and fibrin degradation products on 
cultured endothelial cells, smooth muscles, or macrophage 
has been studied [10]. The interaction of endothelial cell 
monolayer with fibrin caused morphologic change of cells. 
The degree of morphologic hange correlated with the 
concentration of fibrin [11]. Short-term incubation of hu- 
man umbilical vein endothelial cells (HUVECs) with fibrin 
led to increased release of the Von Willebrand factor [12]. 
Fibrin generated by the addition of CaC12 to citrated 
plasma lso altered synthesis of prostacyclin and tissue-type 
plasminogen activator by cultured HUVECs [13]. The 
contact of fibrin with endothelial cell monolayers also 
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increased endothelial permeability to albumin [14]. How- 
ever, the exact mechanisms of the fibrin-induced morpho- 
logic change of endothelial cells are unknown. 
Thrombin has many effects on endothelial cells. For 
example, it stimulates prostacyclin production [15] and 
induces the release of tissue plasminogen activator and 
plasminogen activator-inhibitor f om endothelial cells 
[9,16]. Thrombin might also affect the integrity of mono- 
layers of cultured endothelial cells [17]. Ancrod is a throm- 
bin-like enzyme purified from the venom of Malayan pit 
viper Calloselasma rhodostoma. It selectively releases fib- 
rinopeptide A from fibrinogen [ 18] without activating Fac- 
tor XIII [19] and has little effect on other coagulation 
factors [20]. Through the proteolysis of plasma fibrinogen, 
ancrod causes the formation of non-crosslinked fibrin. 
Ancrod itself did not cause prostacyclin production [21] 
and phosphoinositide breakdown; however, it has been 
reported that ancrod-or reptilase (a thrombin-like n- 
zyme)-generated fibrin caused morphologic change of HU- 
VECs [22,23]. Therefore, we tried to clarify the mecha- 
nism involved. 
2. Materials and methods 
2.1. Materials 
Medium 199, fetal bovine serum (FBS), penicillin and 
streptomycin sulfate were obtained from Gibco (Grand 
Island, NY, USA). Endothelial cell growth supplement 
(ECGS) was obtained from Collaborative Research (Be- 
dford, MA, USA). Collagenase, Gly-Pro-Arg-Pro, dode- 
capeptide of fibrinogen y-chain (residues 400-411), hu- 
man fibrinogen, human thrombin, neomycin, 1,2-bis(2- 
aminophenoxy)ethane-N,N,N' N'-tetraacefic acid/acetoxy- 
methyl ester (BAPTA/AM), EGTA, 8-(N,N'-diethyl- 
amino) octyl-3,4,5-trimethoxybenzoate (TMB-8), pertussis 
toxin (PTX), Dowex-1 (100-200 mesh: X8 chloride form) 
were purchased from Sigma (St. Louis, MO, USA). Mono- 
clonal antibody of a v/33 (23C6) from tissue culture super- 
natant was purchased from Serotec (Oxford, UK). 7E3, a 
monoclonal antibody against platelet glycoprotein lib-Ilia 
complex, which is cross-reactive with a v/33 [24,25] was 
donated by Dr. Barry Coller (State University of New 
York, Stony Brook, NY). Monoclonal antibody AP~, raised 
against platelet glycoprotein Ib [47], recognizing lyco- 
protein Ib-like protein on HUVEC [48,49] was generously 
provided by Dr. Robert Montgomery (Blood Center of 
Southeastern Wisconsin, Milwaukee, MI, USA). 
[3H]Myoinositol was purchased from Amersham (En- 
gland). Ancrod was purified from the venom of Callose- 
lasma rhodostoma (Latoxan, France) through columns of 
Sephadex G-75, DEAE-Sephadex A-50 and heparin- 
Agrose. Subsequently, it was further purified by HPLC 
using a gel filtration column (Protein PAK 300 sw, Wa- 
ters). This purified protein migrated as a single band as 
judged by SDS-PAGE and it contained a single amino- 
terminal residue, valine. Its NH2-terminal sequence (Vai- 
Ile-Gly-Gly-Asp-) is the same as previously reported from 
the cDNA sequence [26]. Ancrod selectively cleaved fib- 
rinopeptide A from fibrinogen as shown by reverse-phase 
HPLC using a C18 column (data not shown). The specific 
activity of this ancrod preparation is around 1000 thrombin 
units per mg in causing blood clot formation. 
2.2. Endothelial cell culture 
HUVECs were prepared as described before [27]. HU- 
VECs were grown in Medium 199 containing 2.2 mg/ml 
of sodium bicarbonate supplemented with 20% heat-in- 
activated FBS, ECGS (150/zg/ml), penicillin (100 U/ml) 
and streptomycin (100 /~g/ml). Cells were grown in 
12-well plates (except as noted) at 37°C under 5% CO 2 
and the medium was replaced at the first day after seeding 
and every two days thereafter. Cells were identified by 
their positive staining for von Willebrand factor antigen by 
indirect immunofluorescence. Confluent primary cultured 
cell monolayers were used 4 to 5 days after the cells were 
seeded. 
2.3. Photography 
Morphology of endothelial cell monolayer was ob- 
served and photographs taken with a camera (Nikon-F301) 
attached to a Nikon inverted phase-contrast microscope. 
2.4. Lactate dehydrogenase activity 
LDH activity was measured as an index of cellular 
damage based on the spectrophotometric method [28]. The 
LDH activity of the cultured medium from HUVECs was 
calculated as the absorbance difference between the prepa- 
rations in the presence (experimental) and absence of 
ancrod (control). LDH produced by HUVECs was com- 
pared (in a percentage basis) with the total LDH of HU- 
VECs pretreated with 0.1% Triton X-100 (v/v). 
2.5. Assay of fibrin degradation products 
FDPs were measured by using Elisa kit (Organon 
Teknika, Boxtel, The Netherlands) according to the manu- 
facturer's procedure. The tagging antibody of Elisa kit, 
anti-FDPs, reacts exclusively with D-containing fibrin 
degradation products but not with purified fibrinogen 
degradation products X and Y. 
2.6. Measurements of inositol phosphates 
The procedure was carried out according to a previously 
described method [29]. In brief, HUVECs were cultured in 
6-well plates and confluent monolayer cells were incu- 
bated for 48 h in growth medium containing 5 /xCi/ml of 
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[3H]myoinositol (specific activity, 16.2 C i /mmol ) ,  then 
cells were washed with PBS and treated with inhibitors for 
indicated time intervals. The experiment was started by 
addition of ancrod to 1 ml of platelet-poor plasma (PPP), 
and LiC1 (10 raM) was added to medium 20 min prior to 
addition of ancrod. Incubation was terminated at the indi- 
cated time intervals by removing the fibrin clot and 500/x l  
of ice-cold trichloroacetic acid (10%, w/v )  were added. 
The mixture was centrifuged at 14000 rpm for 4 min. 
Trichloroacetic acid was removed by extracting the resul- 
tant supernatant with 10 ml of ethyl ether 3-times and the 
residual ethyl ether was finally evaporated off by heating 
samples in warm water at 70°C for 5 min. Samples were 
neutralized with 1 N NaOH to pH 7.2 and loaded onto 
Dowex-1 chromatography columns (bed volume, 1 ml) and 
inositol phosphates were eluted as described previously 
[30]. In this experiment, only [3H]inositoi monophosphate 
was measured as an index of the total inositol phosphate 
formation, because the levels of inositol bisphosphate and 
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Fig. 1. Concentrations of fibrin degradation products (FDPs) in the 
supematants obtained from cultured citrated-plasma edium. The super- 
natant of endothelial cells incubated for the indicated time period in the 
absence (control, []) or presence of ancrod (0.02 U/ml, cross-hatched 
box), or presence of 0.02 U/ml ancrod and 100 kIU/ml aprotinin (ll). 
Non-crosslinked fibrin was generated upon the monolayer of endothelial 
cells in the presence of ancrod (0.02 U/ml). Data are expressed as 
means :t: S.E. (n = 3). 
2.7. Adhes ion assay 
Endothelial cells were grown as monolayers in tissue 
culture plates and metabolically labeled for 72 h with 
[3H]leucine (50 /zC i /ml ;  120 C i /mol ) .  The cells were 
detached with a 0.05% t ryps in /0 .53  mM EDTA solution 
and washed with Medium 199. Finally, cells were sus- 
pended with serum-free Medium 199. Prior to the adhesion 
assay, cells were allowed to incubate with appropriate 
inhibitors (i.e, rhodostomin or antibody 7E3) for 20 min at 
Fig. 2. Phase-contrast microscopic photographs of cultured human umbilical vein endothelial cells. (A) The confluent endothelial cells have normal 
polygonal cobblestone shape in the presence of citrated plasma. (B and C) Effects of ancrod (0.02 U/ml) on HUVECs in the presence of citrated plasma 
were shown. HUVECs were incubated in the presence of ancrod for 6 (B) and 10 (C) hours, respectively. Enlargement of intercellular space among 
individual cell and loss of polygonal cobblestone shape were noted. D-F, HUVECs were pretreated with 1.2 mM EGTA (10 min, D), 50/zM TMB-8 (10 
min, E) or 15 /xM BAPTA/AM (30 min, F) in plasma, then 0.02 U/mi ancrod was added and incubated for 10 h (magnification × 100). 
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37°C. Endothelial cells (2. 10 4 cells/ml) were added to 
individual wells of 96-well polystyrene (non-tissue culture) 
plates that were previously coated with fibrin. 
The fibrin-coated plates were prepared as follow. Fib- 
rinogen (50 /ll of 2 mg/ml ) in Medium 199 was incu- 
bated with ancrod (0.1 U/ml)  in each well at 37°C for 2 h; 
firm clots resulted. Each well was then washed once with 
Medium 199 and further incubated with 1% BSA for 30 
min at 37°C. The plates were washed 3-times with Medium 
199. Radiolabeled HUVEC suspension (0.24 ml; 8.104 
cells/ml) was added to each well and incubated at 37°C. 
Nonadherent cells were removed by aspiration following 
three washes. Finally, 200 /zl of 2 N NaOH with 0.2% 
Triton X-100 was added to each well and radioactivity 
counted. Cell adhesion was expressed in cpm. In the 
absence of adhesive proteins, the radioactivity of the non- 
coated sample was found to be less than 200 cpm. All data 
(cpm) are expressed after subtracting noncoated well ra- 
dioactivity. 
2.8. Statistical analysis 
Statistical significance was determined by the Student's 
t-test, and a P value of < 0.05 was chosen to denote 
statistical significance between control and experimental 
groups. All experiments were repeated at least three times 
from separate preparations. 
3. Results 
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Fig. 4. Effect of compounds on IP 1 formation of HUVECs stimulated by 
ancrod-generated fibrin. [3H]Myo-inositol-labeled HUVECs were incu- 
bated in platelet-poor plasma in the absence (control) or presence of 
Gly-Pro-Arg-Pro (1 mM) or neomycin (1 mM) for 10 min , or HUVECs 
were pretreated with antibodies 23C6 (1:100) or 7E3 (25 /xg/ml) for 20 
min at 37°C following aspiration of the plasma medium and re-addition 
of fresh plasma prior to addition of ancrod (0.02 U/ml). After 30 min 
incubation, IP I levels of HUVECs were determined. Each column repre- 
sents means+ S.E. (n = 4). * : P < 0.05; * * :P < 0.01 as compared with 
control. 
increase at 10 and 24 h incubation period, respectively, 
Fig. 1). This increase of FDPs was completely inhibited by 
pretreatment of aprotinin (100 kIU/ml). It has been re- 
ported that FDPs caused morphologic hange and altered 
permeability of endothelial cell monolayer [31-33]. Apro- 
tinin, a serine proteinase inhibitor [32], inhibited FDPs 
production during the experimental period (Fig. 1), thus it 
was used to prevent he disturbance of HUVECs by FDPs 
in the following experiment. 
Non-crosslinked fibrin formed upon HUVEC monolay- 
ers caused a significant increase of FDPs (1.8- and 7-fold 
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Fig. 3. Inositol monophosphate formation of [3H]inositol-labeled HU- 
VECs caused by ancrod in plasma medium. Endothelial cells were 
pretreated with 10 mM LiCI and incubated in platelet-poor plasma 
medium, then ancrod (11, 0.005 U/ml; O, 0.01 U/ml; A, 0.02 U/ml)  
was added to cultured HUVECs and incubated at 37°C for various time 
intervals. At the indicated time periods, reactions were quenched by the 
addition of trichloroacetic acid. IP l level was determined as described in 
Section 2. IP 1 levels were very low throughout experimental time-course 
if ancrod was absent (©). Values are expressed as means + S.E. (n = 6). 
Ancrod (0.01-10 U/ml)  did not alter the morphology 
of HUVEC in FBS-free medium during a 24 h incubation 
(data not shown). However, their morphology was altered 
in response to fibrin generated by ancrod in the presence 
of citrated platelet-poor plasma (Fig. 2). The cells lost their 
polygonal cobblestone shape and separated in part from 
adjacent cells, and the intercellular spaces widened when 
the incubation period was prolonged. This change was 
observed initially within the first 2-6 h and became more 
prominent during a 10 h incubation period. Alteration of 
HUVEC morphology was prevented by pretreatment of
Gly-Pro-Arg-Pro (4 mg/ml), which prevented fibrin clot 
formation for 10 h (data not shown), indicating that this 
morphologic hange was caused by polymerized fibrin 
generated by ancrod. 
3.3. Lactate dehydrogenase release 
This cell morphologic hange was not accompanied by 
lactate dehydrogenase release from HUVECs. Ancrod it- 
M.-C. Chang et al. / Biochimica et Biophysica Acta 1269 (1995) 115-121 119 
self did not elevate LDH level from HUVECs in serum-free 
medium. When endothelial cells were incubated in citrated 
platelet-poor plasma medium for 24 h, the LDH level was 
neither elevated. Lower than 5% of total LDH release from 
HUVECs was detected even after ancrod was added to 
plasma medium for 24 h (data not shown). 
3.4. Effect of calcium on morphology of HUVEC 
Calcium chelators EGTA (1.2 mM), and BAPTA/AM 
(15 p~M loading for 30 min), or TMB-8 (50 izM) which is 
an inhibitor of intracellular calcium mobilization [34], 
pronouncedly prevented morphologic hange of endothe- 
lial cell monolayers causedL by ancrod in the presence of 
plasma (Fig. 2D-F). 
3.5. Phosphoinositide breakdown in HUVECs 
Ancrod itself did not stimulate IPj formation of HU- 
VECs in serum-free medium at concentrations of 0.02-1.0 
U/ml. However, IP 1 production increased if ancrod was 
added to citrated plasma upon HUVECs (Fig. 3). At 0.02 
U/ml, ancrod increased IPt production at a faster fashion 
than ancrod at 0.01 or 0.005 U/ml  did. Ancrod (0.02 
U/ml)  in plasma medium caused a significant increase of 
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Fig. 5. Effect of pertussis toxin treatment on IP 1 accumulation of HU- 
VECs in response to ancrod-generated fibrin. [3H]Myo-inositol-labeled 
cells were pretreated with PTX (100 ng/ml)  at 37°C for 16 hours. The 
cells were challenged for 15, 30 and 60 min with 0.02 U /ml  of ancrod in 
aprotinin (100 klU/ml)-containing plasma, then IP 1 level was measured. 
Data are expressed as factors relative to resting value at zero time 
(mean + S.E.M., n = 5). (O) Cells without PTX treatment, and (0 )  cells 
pretreated with PTX. * : P < 0.05; * * : P < 0.01 as compared with 
respective control. 
30 min. IP 1 level began to run down when a fibrin plate 
was formed at the first hour after addition of ancrod (0.02 
U/m). At 0.01 and 0.005 U/ml,  ancrod increased IP l 
level at a slower rate, reaching the maximal evel at the 
first 1 and 2 h, respectively. 
Fig. 6. The inhibitory effect of the monoclonal antibody against ot v fl 3 integrin receptor on the morphologic hanges of HUVEC caused by ancrod. 
HUVECs were pretreated with either normal saline (A and B), or 23C6 (C, 1:100), or 7E3 (D, 25 /~g/ml), non-immune mouse IgG (E, 1:50), or 
dodecapeptide of fibrinogen ~, chitin (F, 500/zM) in citrated plasma. Then 0.02 U /ml  of ancrod (B-F) was added to trigger fibrin formation. Morphology 
of HUVEC monolayers was examined by a phase-contrast microscope 10 h after ancrod addition. (magnification × 100). 
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IP 1 increment was completely inhibited by Gly-Pro- 
Arg-Pro (1 mg/ml), which completely prevented fibrin 
formation through the experimental period (30 min). Both 
monoclonal antibodies 23C6 (100-fold dilution) and 7E3 
(25 /zg/ml), but not AP 1 (80 /zg/ml, data not shown), 
significantly inhibited the IP~ increment. The increase of 
IP~ caused by fibrin was sensitive to 1 mM of neomycin 
(70% inhibition) (Fig. 4). However, mepacrine (50/zM) or 
aspirin (10/~M), which blocks phospholipase A 2 or  cyclo- 
oxygenase activity, respectively, did not affect the IP~ 
production caused by ancrod-generated fibrin (data not 
shown). 
3.6. Effect of  pertussis toxin pretreatment 
PTX pretreatment (100 ng/ml, 16 h) significantly in- 
hibited the increase of IP 1 by ancrod in HUVECs cultured 
in citrated plasma (Fig. 5). 
3. 7. Role of  aL~/33 integrin of HUVECs in fibrin-induced 
morphologic alteration 
As shown in Fig. 6, HUVECs pretreated with 23C6 
(100-fold dilution) or 7E3 (25 /zg/ml) in plasma for 20 
min at 37°C followed by aspiration and re-addition of fresh 
aprotinin-containing plasma, these pretreatment did not 
perturb endothelial cells morphology through experiment 
periods. However, these pretreatments prevented cell mor- 
phologic alteration caused by ancrod-generated fibrin. Do- 
decapeptide of fibrinogen y-chain (y 400-411, 500 ~M) 
showed little effect on the morphologic change. 
4. Discussion 
It is well known that thrombin stimulates prostacyclin 
production [15] and causes shape change of endothelial 
cells [17]. Ancrod, unlike thrombin, did not induce prosta- 
cyclin production and cell morphologic change at concen- 
trations of 0.01-10 U/ml. However, when ancrod was 
added to cultured HUVECs in the presence of citrated 
plasma, it caused fibrin formation upon cell monolayers 
leading to the alteration of cell morphology. The cellular 
shape change was prevented by Gly-Pro-Arg-Pro, an ana- 
logue of the amino terminus of the A a-chain of the fibrin 
monomer. This tetrapeptide inhibits fibrin polymerization 
by binding to the site complementary to the A a-chain 
polymerization site and thus disrupting the interactions 
between these complementary binding sites [35]. This re- 
sult indicates that morphologic change of HUVEC is caused 
by polymerized fibrin. This morphologic change caused by 
ancrod-generated fibrin was in concert with the results 
reported with fibrin generated by reptilase and thrombin 
[11,22,23]. However, ancrod-generated fibrin did not cause 
LDH release from HUVEC during a 24 h incubation after 
its addition to plasma. 
Many reports also indicate that cell morphology is 
intimately related to increased intracellular Ca 2÷ [36,37]. 
The morphologic alteration caused by ancrod-generated 
fibrin was prevented either by extra- or by intra-cellular 
calcium chelators (EGTA and BAPTA/AM, respectively). 
TMB-8, an inhibitor of intracellular calcium mobilization, 
also prevented cell morphologic hange caused by non- 
crosslinked fibrin. Therefore, the morphologic hange of 
HUVEC in response to fibrin might be caused by the 
mobilization of intra- and extra-cellular calcium. 
Upon binding to endothelial cell surface, many extracel- 
lular signalling molecules elicit biological responses by 
activating inositol phospholipid-specific phospholipase C 
[38]. In addition, Tang et al. observed that a v/33 co-local- 
ized with stress fiber endings, suggesting a potential sig- 
nalling function of this integrin across the cell membrane 
[39]. Several ines have suggested that integrins may trans- 
duce signal from ligands by triggering intraceilular events 
and its function is dependent on calcium [40]. Therefore, 
we further examined if phosphoinositide breakdown is 
involved in this morphologic hange of HUVECs in re- 
sponse to fibrin. In this study, we first demonstrated that 
ancrod-generated fibrin caused phosphoinositide break- 
down of HUVECs although this phosphoinositide break- 
down was much smaller compared with that increment by 
10 /xM of histamine (20%). The increase of IP l was 
marked within the first 15 min, reaching to the maximal 
level at 30 min following the addition of 0.02 U/ml 
ancrod to citrated plasma. The increment of IP 1 was pre- 
vented by Gly-Pro-Arg-Pro, an inhibitor of fibrin poly- 
merization indicating that ancrod-generated fibrin caused 
phosphoinositide breakdown of HUVECs. The phospho- 
inositide breakdown is sensitive to mAbs against a v 133. 
Neomycin, an inhibitor of phosphoinositide breakdown 
[41,42], significantly inhibited the phosphoinositide break- 
down. On the other hand, mepacrine and aspirin, inhibitors 
of phospholipase A 2 and cyclooxygenase, r spectively, did 
not affect the increased turnover of phosphoinositides of 
HUVECs in response to fibrin, thus excluding the involve- 
ment of cyclooxygenase products in mediating the mor- 
phologic hange of HUVEC. 
Several ines of evidences have implicated a mandatory 
role for a G-protein in signal transduction from certain 
receptors to phospholipase C and that there might be two 
distinct types (PTX-sensitive and -insensitive) of such 
G-proteins [43]. From the inhibitory effect of PTX on IP 1 
production indicated that phosphoinositide breakdown 
caused by ancrod-generated fibrin is linked to activation of 
a PTX-sensitive G-protein. 
In the present study, both 23C6 and 7E3, monoclonal 
antibodies against a v/33, pronouncedly prevented the mor- 
phology of HUVECs in response to fibrin generated by 
ancrod. Furthermore, HUVEC attachment toancrod-gener- 
ated fibrin was also markedly inhibited by GRGDS and 
mAbs against a v/33 (unpublished observation). The adhe- 
sion of endothelial cells to fibrinogen is mediated through 
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Arg-Gly-Asp (RGD) sites that interact with the integrin 
receptor av/33 [44-46]. These results indicate that the 
interaction of endothelial cells with ancrod-generated fib-
fin is mainly triggered by a~ v/33 integrin binding, although 
the subsequent signal transduction pathways may be differ- 
ent for cell adhesion and morphological change. 
From the present data, we suggest that both intra- and 
extra-cellular calcium participate in the morphologic alter- 
ation caused by ancrod-generated fibrin and the fibrin 
causes phosphoinositide breakdown mainly through the 
binding of a v/33 integrin ~aad the activation of a pertussis 
toxin-sensitive G-protein coupled endogenous phospho- 
lipase C. However, other possible pathways involving with 
protein kinase C or other kinases are not excluded. 
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